FS Development Corp.

Completed 2021-02-05
  • CIK 1816736
  • FSDC
  • Now GMTX
  • IPO 2020-08-13
  • $121M trust
  • 757 filings

Successfully merged with Gemini Therapeutics, Inc. • Now trading as GMTX

IPO Size
$121M
raised at the IPO
Trust
$121M
as of 2020-12-31
Current Status
Completed
from its latest filing
IPO Year
2020
year it listed

Filings, by quarter

757 filings over 25 quarters; violet bars carry a milestone

  1. 20 Q3: 21 filings
  2. 20 Q4: 16 filings
  3. 21 Q1: 55 filings
  4. 21 Q2: 26 filings
  5. 21 Q3: 9 filings
  6. 21 Q4: 18 filings
  7. 22 Q1: 27 filings
  8. 22 Q2: 6 filings
  9. 22 Q3: 7 filings
  10. 22 Q4: 31 filings
  11. 23 Q1: 65 filings
  12. 23 Q2: 34 filings
  13. 23 Q3: 23 filings
  14. 23 Q4: 46 filings
  15. 24 Q1: 37 filings
  16. 24 Q2: 29 filings
  17. 24 Q3: 12 filings
  18. 24 Q4: 29 filings
  19. 25 Q1: 41 filings
  20. 25 Q2: 24 filings
  21. 25 Q3: 42 filings
  22. 25 Q4: 66 filings
  23. 26 Q1: 34 filings
  24. 26 Q2: 28 filings
  25. 26 Q3: 31 filings
  • S-1 filed 20 Q3
  • IPO 20 Q3
  • Definitive agreement 20 Q4
  • Completed 21 Q1

SPAC Overview

Where it stands on the road from S-1 to merger

Timeline Progress

About

FS Development Corp. is a blank-check company formed to effect a merger, acquisition, or similar business combination. It intends to capitalize on its management’s background and experience to identify opportunities in the biotechnology sector, with a primary focus on U.S. healthcare.

Investment Focus

Biopharmaceuticals

Geographic Focus

United States

Key Information

As the filings state it

IPO Date
2020-08-13
Total Redemptions
$1.1K
PIPE
$95.1M
SIC
6770
Completion Date
2021-02-05
Merger Target
Gemini Therapeutics, Inc.
SPAC Ticker
FSDC
Merged Ticker
GMTX

SPAC Team

The banks on its IPO, and the team as the filings describe it

Underwriters

Extended Team Information

The team includes Foresite Capital co-founder Jim Tananbaum, healthcare and life-sciences investors and executives, and experienced leaders in biotechnology, healthcare investment banking, and drug development. Foresite Capital reports a substantial biotechnology investment and financing history.

External Resources